Literature DB >> 21030893

Cauda equina syndrome in ankylosing spondylitis: successful treatment with lumboperitoneal shunting.

Hang-Korng Ea1, Frédéric Lioté, Guillaume Lot, Thomas Bardin.   

Abstract

STUDY
DESIGN: Retrospective study.
OBJECTIVE: To assess outcomes after lumboperitoneal shunting for CES with dural sac dilation and multiple arachnoid diverticula in patients with long-standing AS. SUMMARY OF BACKGROUND DATA: Cauda equina syndrome (CES) is a rare complication of long-standing ankylosing spondylitis (AS). Neurologic symptoms occur insidiously and have a poor prognosis without effective treatment.
METHODS: We retrospectively studied cases seen between 1997 and 2009 at our university-hospital rheumatology department.
RESULTS: We identified 9 patients with AS and dural sac dilation (mean age: 64, range: 38-75), of whom 8 experienced CES 29.1 years on average (range: 10-51) after AS onset. Presenting symptoms were urinary abnormalities (n = 4), sensory abnormalities (n = 6), or radicular or low back pain (n = 4). The symptoms worsened progressively, with mild (n = 3) to severe (n = 1) motor deficiency, sphincter dysfunction (urinary [n = 6] and/or anal [n = 4] sphincter), and impotence (n = 3). Magnetic resonance imaging showed dural sac dilation (n = 9), multiple lumbar arachnoid diverticula (n = 6), erosions of the laminae and spinous processes (n = 6), and nerve-root tethering (n = 6) with adhesion to the dura mater and vertebrae (n = 7). Cerebrospinal fluid (CSF) flow study by magnetic resonance imaging was performed in 2 patients and showed communication of the diverticula with the CSF. Lumboperitoneal shunting, performed in 5 patients, was followed by improvements in sensation (n = 4), urinary symptoms (n = 2), anal continence (n = 3), and pain. Full recovery of muscle strength was noted in 3 patients. Improvements persisted after a mean of 49 months (range: 18-96).
CONCLUSION: Lumboperitoneal shunting induced substantial improvements in all 5 patients treated with this procedure. This result suggests that AS-related CES may be due to chronic arachnoiditis and dural fibrosis leading to diminished CSF resorption with dural sac dilation and diverticula formation.

Entities:  

Mesh:

Year:  2010        PMID: 21030893     DOI: 10.1097/BRS.0b013e3181e8fdd6

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  7 in total

1.  Symptomatic intrathecal hypertension.

Authors:  Awss Zidan; Deborah Young Bradshaw
Journal:  Neurol Clin Pract       Date:  2015-12

Review 2.  Physical therapy and surgery.

Authors:  Rafael Valle-Onate; Michael M Ward; Gail S Kerr
Journal:  Am J Med Sci       Date:  2012-05       Impact factor: 2.378

Review 3.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

Review 4.  Rehabilitation and surgical management of ankylosing spondylitis.

Authors:  E Lubrano; D Astorri; M Taddeo; A Salzmann; E Cesarano; L Brunese; M Giganti; A Spadaro
Journal:  Musculoskelet Surg       Date:  2013-08-15

Review 5.  Outcomes Reported After Surgery for Cauda Equina Syndrome: A Systematic Literature Review.

Authors:  Nisaharan Srikandarajah; Martin Wilby; Simon Clark; Adam Noble; Paula Williamson; Tony Marson
Journal:  Spine (Phila Pa 1976)       Date:  2018-09-01       Impact factor: 3.241

6.  Lumbar bone erosion with anterior dural ectasia in ankylosing spondylitis: a case report.

Authors:  Zhi-Xiang Huang; Wei-Ming Deng; Xin Guo; Chu-Lan Lin; Tian-Wang Li
Journal:  J Int Med Res       Date:  2019-02-19       Impact factor: 1.671

7.  Ankylosing spondylitis: etiology, pathogenesis, and treatments.

Authors:  Xu Cao; Xisheng Weng; Wei Zhu; Xuxia He; Kaiyuan Cheng; Linjie Zhang; Di Chen; Xiao Wang; Guixing Qiu
Journal:  Bone Res       Date:  2019-08-05       Impact factor: 13.567

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.